-
公开(公告)号：US20250127890A1
公开(公告)日：2025-04-24
申请号：US18570121
申请日：2022-10-11
Inventor： Naushad ALI , Mark M. HUYCKE
IPC: A61K39/395 , A61K45/06 , A61P31/14 , C07K16/40 , C12N15/113 , G01N33/569
Abstract: Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.
-
公开(公告)号：US12264305B2
公开(公告)日：2025-04-01
申请号：US16574587
申请日：2019-09-18
Applicant: Board of Regents, The University of Texas System , THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
Inventor： Young-tae Kim , Loan Bui , James Battiste , Xue Cai , Michael Sughrue
Abstract: A method and device for isolating a migratory cell population from a mixed population of migratory cells and non-migratory cells is described herein. The method comprises placing the mixed population of migratory cells and non-migratory cells in contact with a device having one or more microchannels; and isolating the migratory cell population within the microchannels following an incubation period, wherein the one or more microchannels have an average size in a proliferation direction of the migratory cells that is less than a minimum proliferation space of the migratory cells along the proliferation direction.
-
公开(公告)号：US20240425534A1
公开(公告)日：2024-12-26
申请号：US18379715
申请日：2023-10-13
Inventor： Adam Duerfeldt , Xiaozheng Dou , Ziwei Hu
Abstract: Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.
-
公开(公告)号：US20240423976A1
公开(公告)日：2024-12-26
申请号：US18749968
申请日：2024-06-21
Inventor： Vibhuti AGRAHARI , Neeraj S. THAKUR
Abstract: A method and composition for mitigating or reducing drug-induced ototoxicity or drug-induced hearing loss in a subject in need of such treatment, comprising: providing a drug delivery system which releases a therapeutic drug upon exposure to reactive oxygen species, wherein the drug delivery system comprises a thermoresponsive hydrogel containing therapeutic drug-loaded crosslinked hybrid nanoparticles and provides sustained therapeutic drug release. The crosslinked hybrid nanoparticles within which the therapeutic drug is loaded may comprise 10,12-Pentacosadiynoic acid (PCDA) and polypropylene sulfide-polyethylene glycol monomethyl ether (PPS-mPEG). The drug-induced ototoxicity or hearing loss may be caused by cisplatin or other platinum-based drugs.
-
公开(公告)号：US20240417808A1
公开(公告)日：2024-12-19
申请号：US18752771
申请日：2024-06-24
Inventor： Maria Jesus Ruiz Echevarria
IPC: C12Q1/6886
Abstract: An assay system and method for generating quantitative data for a subject and a method for treating prostate cancer in a subject by determining an expression level of a biomarker panel in a sample obtained from the subject, the biomarker panel including the genes CDC45, CENPI, CLSPN, ERCC6L, EXO1, NCAPG, BUB1B, CDK1, NUSAP1, RAD51, and RRM2 and optionally E2F7 and/or GSG2, wherein the expression level is obtained by measuring expression of the biomarker panel in the sample, and wherein the subject has a cancer, or is suspected of having a cancer. The cancer may be, for example, prostate cancer, brain cancer, lung cancer, breast cancer, bladder cancer, or ovarian cancer.
-
Patent Agency Ranking
公开(公告)号：US20240379240A1
公开(公告)日：2024-11-14
申请号：US18631773
申请日：2024-04-10
Inventor： Chongle PAN , Adrien F. BADRE
Abstract: Provided herein are methods of using multi-task learning (MTL) neural network architecture for predicting many disease traits of an individual from their whole genome. The model used a shared latent genomic representation, and each trait was predicted from the shared representation via a task-specific hidden layer. The MTL models achieved higher predictive performance than single-task learning (STL) models for both cancer and non-cancer diseases.
-
公开(公告)号：US12143061B2
公开(公告)日：2024-11-12
申请号：US17989044
申请日：2022-11-17
Inventor： Andres F. Cavieres Pinilla
Abstract: A mounting system for mounting a solar panel assembly to a base assembly includes a panel support bracket, a base bracket and a clamp configured to exert a compressive force to hold the panel support bracket and the base bracket together. The clamp comprises a V-shaped clamp body that includes a pair of legs that are spring-loaded to oppose an approximation of the legs by an external compressive force. The clamp includes a pair of receiver slots, with each of the pair of receiver slots located on a corresponding one of the pair of legs. The pair of receiver slots collectively provides a clearance to admit the panel support bracket and the base bracket when the legs are compressed together.
-
公开(公告)号：US20240325788A1
公开(公告)日：2024-10-03
申请号：US18575470
申请日：2022-06-29
Applicant: The Regents of the University of California , The Board of Regents of the University of Oklahoma
Inventor： Liangzhong XIANG , Yong CHEN
IPC: A61N5/10
CPC classification number: A61N5/1049 , A61N5/103 , A61N5/1064 , A61N5/1071 , A61N2005/1058 , A61N2005/1087 , A61N2005/1092
Abstract: Proton beams can deliver a highly targeted radiation dose to a narrow volume defined by their Bragg peaks. However, Bragg peak range uncertainties persist during dose delivery. Fortunately, pulsed proton beams generate protoacoustic emissions proportional to absorbed proton energy, thereby encoding dosimetry information in a detectable acoustic wave. The present embodiments provide methods and apparatuses to derive and model protoacoustic imaging with an ultrasound transducer, and examine the frequency characteristics of protoacoustic emissions, which are crucial parameters in imaging resolution.
-
9.发明公开公开(公告)号：US20240280665A1
公开(公告)日：2024-08-22
申请号：US18694705
申请日：2023-10-13
Inventor： Jay W. McDaniel , Justin G. Metcalf , Rachel E. Jarvis
CPC classification number: G01S7/292 , G01S7/32 , G01S7/411 , G01S13/282
Abstract: A method comprising: obtaining I/Q data associated with a received radar signal; performing background subtraction on the I/Q data to obtain a subtracted signal; applying an algorithm to the subtracted signal to obtain a filtered signal, wherein the algorithm is based on a MSE filter; performing time-gating on the filtered signal to obtain a time-gated signal; applying a FFT to convert the time-gated signal to a frequency-domain signal; and applying a calibration set to the frequency-domain signal to extract an RCS of an OUT; and a system for conducting the method.
-
公开(公告)号：US11999677B2
公开(公告)日：2024-06-04
申请号：US17666692
申请日：2022-02-08
Inventor： Weidong Wang , Venkateswararao Eeda
IPC: C07C233/73 , A61K31/166 , A61P3/10 , C07C237/22 , C07C311/46 , C07D213/40 , C07D231/56 , C07D317/54
CPC classification number: C07C233/73 , C07D317/54
Abstract: Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic β-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
-
-
-
-
-
-
-
-
-
Search Results
492
records
(took 0.035 seconds)
